Cronos Group Announces Closing of Previously Announced $17 Million Bought Deal
TORONTO, Nov. 8, 2017 /CNW/ – Cronos Group Inc. (TSX-V: MJN) (OTC – Nasdaq Int’l Designation: PRMCF) (“Cronos Group”) is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option. As such, a total of 5,476,190 common shares of Cronos Group (the “Shares”) were sold at a price of $3.15 per Share for aggregate gross proceeds of approximately $17.2 million (the “Offering”).
The Offering was underwritten by a syndicate led by PI Financial Corp. as sole bookrunner and which included Canaccord Genuity Corp.
Cronos Group intends to use the net proceeds of the Offering for expanding production capacity at its wholly-owned Licensed Producer Peace Naturals Project Inc., developing infrastructure for distribution, research and development initiatives, and for general working capital purposes.
The Shares were offered by way of a short form prospectus filed by Cronos Group in each of the provinces of Canada, excluding the province of Québec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions. The securities that were sold have not been, nor will they be, registered under the U.S. Securities Act, and were not offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements.
About Cronos Group
Cronos Group is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers (“LPs”) regulated within Health Canada’s Access to Cannabis for Medical Purposes Regulations and holds a portfolio of minority investments in other Licensed Producers. The Company’s flagship LPs, Peace Naturals Project Inc. (Ontario) and Original BC Ltd. (British Columbia), are collectively situated on over 125 acres of agricultural, licensed land. Cronos Group is focused on building an international iconic brand portfolio, providing patients with personalized care, and creating value for our shareholders.
